Polysaccharide typhoid vaccine has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Polysaccharide typhoid vaccine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
219550-012 (Typh-012) IV Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) injected in healthy children and adults according to the Indian prescribing information. Typherix™: GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (Typh).
270362/010 & 270362/011 (TypHA-010& 011) IV A phase IV, open study of re-vaccination with GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) in subjects, who were previously administered a primary vaccination with GlaxoSmithKline Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine (HEPATYRIX™) or with GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine, TYPHERIX™. TYPHERIX™ (Typh): GlaxoSmithKline (GSK) Biologicals’ Vi polysaccharide typhoid vaccine HEPATYRIX™ (Hepa): GSK Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine